PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea · Delayed Price · Currency is KRW 578,000
+31,000 (5.67%)
Sep 26, 2025, 3:30 PM KST
PharmaResearch Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 449,809 | 350,115 | 261,011 | 194,759 | 154,083 | 108,746 | Upgrade |
Other Revenue | - | - | -0 | -0 | -0 | - | Upgrade |
| 449,809 | 350,115 | 261,011 | 194,759 | 154,083 | 108,746 | Upgrade | |
Revenue Growth (YoY) | 51.66% | 34.14% | 34.02% | 26.40% | 41.69% | 29.66% | Upgrade |
Cost of Revenue | 116,950 | 98,878 | 70,753 | 53,246 | 45,750 | 35,850 | Upgrade |
Gross Profit | 332,859 | 251,237 | 190,258 | 141,513 | 108,333 | 72,896 | Upgrade |
Selling, General & Admin | 126,177 | 94,670 | 73,828 | 58,572 | 42,832 | 29,604 | Upgrade |
Research & Development | 27,175 | 21,176 | 15,030 | 8,702 | 6,738 | 5,543 | Upgrade |
Other Operating Expenses | 716.25 | 618.58 | 556.23 | 648.65 | 313.55 | 240.17 | Upgrade |
Operating Expenses | 163,626 | 125,187 | 98,001 | 75,597 | 55,844 | 39,471 | Upgrade |
Operating Income | 169,233 | 126,051 | 92,258 | 65,916 | 52,489 | 33,426 | Upgrade |
Interest Expense | -9,544 | -4,634 | -2,987 | -3,830 | -1,314 | -1,787 | Upgrade |
Interest & Investment Income | 13,277 | 10,174 | 7,403 | 5,272 | 3,726 | 2,098 | Upgrade |
Currency Exchange Gain (Loss) | -1,232 | 4,955 | -379.95 | 207.69 | 155.77 | 163.98 | Upgrade |
Other Non Operating Income (Expenses) | -11,476 | -6,028 | 3,396 | -3,220 | 124.32 | 4,338 | Upgrade |
EBT Excluding Unusual Items | 160,257 | 130,517 | 99,690 | 64,346 | 55,181 | 38,239 | Upgrade |
Gain (Loss) on Sale of Investments | -3,236 | -14,238 | 4,210 | -5,023 | 1,462 | 2,907 | Upgrade |
Gain (Loss) on Sale of Assets | -191.66 | -11.92 | 36.11 | -113.69 | 229.6 | -362.6 | Upgrade |
Asset Writedown | - | - | -3,231 | -5,161 | -839.66 | -1,246 | Upgrade |
Other Unusual Items | -454.59 | -454.59 | - | - | - | - | Upgrade |
Pretax Income | 156,375 | 115,813 | 100,705 | 54,048 | 56,033 | 39,537 | Upgrade |
Income Tax Expense | 36,383 | 26,870 | 23,440 | 10,614 | 9,210 | 7,085 | Upgrade |
Earnings From Continuing Operations | 119,991 | 88,943 | 77,265 | 43,434 | 46,824 | 32,452 | Upgrade |
Minority Interest in Earnings | 7,002 | 3,100 | -713.44 | -2,857 | -134.98 | 322.11 | Upgrade |
Net Income | 126,993 | 92,043 | 76,551 | 40,577 | 46,689 | 32,774 | Upgrade |
Net Income to Common | 126,993 | 92,043 | 76,551 | 40,577 | 46,689 | 32,774 | Upgrade |
Net Income Growth | 39.95% | 20.24% | 88.66% | -13.09% | 42.45% | 96.64% | Upgrade |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade |
Shares Outstanding (Diluted) | 11 | 10 | 11 | 10 | 10 | 10 | Upgrade |
Shares Change (YoY) | 2.29% | -2.50% | 5.85% | -0.76% | 5.74% | 0.73% | Upgrade |
EPS (Basic) | 12241.81 | 8940.87 | 7571.24 | 4067.47 | 4716.62 | 3447.46 | Upgrade |
EPS (Diluted) | 12241.81 | 8940.87 | 7487.07 | 4067.00 | 4714.88 | 3447.00 | Upgrade |
EPS Growth | 47.87% | 19.42% | 84.09% | -13.74% | 36.78% | 95.19% | Upgrade |
Free Cash Flow | 113,217 | 101,707 | 52,883 | 42,147 | 44,652 | -2,393 | Upgrade |
Free Cash Flow Per Share | 10485.68 | 9879.60 | 5008.31 | 4224.85 | 4441.83 | -251.75 | Upgrade |
Dividend Per Share | 1100.000 | 1100.000 | 950.000 | 660.000 | 600.000 | 500.000 | Upgrade |
Dividend Growth | 15.79% | 15.79% | 43.94% | 10.00% | 20.00% | 66.67% | Upgrade |
Gross Margin | 74.00% | 71.76% | 72.89% | 72.66% | 70.31% | 67.03% | Upgrade |
Operating Margin | 37.62% | 36.00% | 35.35% | 33.84% | 34.06% | 30.74% | Upgrade |
Profit Margin | 28.23% | 26.29% | 29.33% | 20.83% | 30.30% | 30.14% | Upgrade |
Free Cash Flow Margin | 25.17% | 29.05% | 20.26% | 21.64% | 28.98% | -2.20% | Upgrade |
EBITDA | 184,301 | 139,696 | 104,253 | 76,518 | 62,041 | 41,786 | Upgrade |
EBITDA Margin | 40.97% | 39.90% | 39.94% | 39.29% | 40.27% | 38.42% | Upgrade |
D&A For EBITDA | 15,068 | 13,645 | 11,996 | 10,602 | 9,552 | 8,360 | Upgrade |
EBIT | 169,233 | 126,051 | 92,258 | 65,916 | 52,489 | 33,426 | Upgrade |
EBIT Margin | 37.62% | 36.00% | 35.35% | 33.84% | 34.06% | 30.74% | Upgrade |
Effective Tax Rate | 23.27% | 23.20% | 23.28% | 19.64% | 16.44% | 17.92% | Upgrade |
Advertising Expenses | - | 29,642 | 22,601 | 18,381 | 9,339 | 5,711 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.